

Tuberculosis Agents



Included Products: Pretomanid, Priftin (rifapentine), Sirturo (bedaquiline)

Created: 03/12/2020

Revised: 07/13/2023

Reviewed: 07/13/2023

Updated: 08/01/2023

Tuberculosis

Initial Criteria		If yes	If no
1.	Is the member being treated for active tuberculosis at a county clinic with a state funded TB program?	Do not approve.	Continue to #2.
2.	Does the member have a diagnosis of latent tuberculosis infection?	Continue to #3.	Continue to #4.
3.	Is the request for Priftin in combination with isoniazid (INH)?	Approve for 12 weeks.	Continue to #4.
4.	Is the request for Priftin as a part of a multi-drug regimen for active TB without drug resistance?	Approve for 24 weeks.	Continue to #5.
5.	Is the request from an infectious disease specialist (or in consultation with an infectious disease specialist) and they have provided documentation of multidrug resistant TB?	Approve for 24 weeks.	Do not approve

References

- Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020; 69: 1-11.
- Provisional CDC Guidance for the Use of Pretomanid as part of a Regimen [Bedaquiline, Pretomanid, and Linezolid (BPaL)] to Treat Drug-Resistant Tuberculosis Disease. Centers for Disease Control and Prevention. Updated May 4, 2023.
- Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2019; 200 (10): 1208-1218